Novavax, Inc. (NVAX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$10.82

P/E Ratio

N/A

Market Cap

$1.73B

Loading...
Description

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Metrics

Overview

  • HQGaithersburg, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerNVAX
  • Price$10.82+10.86%

Trading Information

  • Market cap$1.73B
  • Float95.51%
  • Average Daily Volume (1m)4,013,542
  • Average Daily Volume (3m)5,282,184
  • EPS-$2.16

Company

  • Revenue$885.19M
  • Rev growth (1yr)-54.80%
  • Net income-$121.30M
  • Gross margin30.40%
  • EBITDA margin-138.53%
  • EBITDA-$117.07M
  • EV$1.33B
  • EV/Revenue1.51
  • P/EN/A
  • P/S1.96
  • P/BN/A
Documents
Wikipedia